医学
慢性便秘
随机对照试验
内科学
安慰剂
便秘
比沙科迪
排便
胃肠病学
慢性病
卢比罗斯通
物理疗法
临床试验
作者
Nutchanun Preechakawin,Monthira Maneerattanaporn,Tanawat Geeratragool,Prachaya Srivanitchapoom,Yuvadee Pitakpatapee,Somchai Leelakusolvong
标识
DOI:10.14309/ajg.0000000000003771
摘要
INTRODUCTION: Constipation, a prevalent nonmotor symptom in Parkinson disease (PD), adversely affects patients' quality of life. Prucalopride, a selective serotonin type 4 receptor agonist, has shown efficacy as a treatment of functional constipation, but its role in PD-related constipation remains underexplored. The objective of this study was to assess the efficacy, safety, and quality-of-life impact of prucalopride in PD patients with chronic constipation. METHODS: In this double-blind randomized controlled trial, PD patients with chronic constipation received prucalopride (2 mg) or placebo once daily for 8 weeks. The primary outcome was the change in the number of spontaneous bowel movements (SBMs) per week from baseline to week 8. Secondary outcomes included stool consistency, straining, and changes in Patient Assessment of Constipation-Symptoms and Patient Assessment of Constipation-Quality of Life scores. Parkinsonian motor severity was assessed using the Unified Parkinson Disease Rating Scale. RESULTS: Fifty-seven patients were included (prucalopride = 30, placebo = 27). At week 8, the change in the number of weekly SBMs was significantly larger in the prucalopride group (3.2 ± 2.8) than in the placebo group (1.6 ± 1.9; P = 0.02). Longitudinal analysis confirmed a significantly higher SBM frequency in the prucalopride group throughout the 8-week period ( P = 0.015). Secondary outcomes showed trends toward improvement but no statistically significant differences. No serious adverse events were reported, and Unified Parkinson Disease Rating Scale scores remained unchanged. DISCUSSION: Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population.
科研通智能强力驱动
Strongly Powered by AbleSci AI